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RESEARCH
We describe the frequency, demographic and clinical fea-
tures, and visual outcomes of ocular syphilis infections ob-
served during 2012–2015 at a tertiary reference center in 
Paris, France. Twenty-one cases (29 eyes) were identified. 
The occurrence of ocular syphilis increased from 1 case in 
2012 to 5 cases in 2013, 6 cases in 2014, and 9 cases 
in 2015 (2.22–25.21/1,000 individual patients/year for the 
period). Among case-patients, an annual 20%–33% were 
co-infected with HIV. Seventy-six percent of ocular syphilis 
infections occurred in men who have sex with men. Seven-
ty-five percent of case-patients had a good final visual out-
come (best-corrected visual acuity >0.3 logMAR score). 
Visual outcome was worse for HIV-positive patients than 
for HIV-negative patients (p = 0.0139). At follow-up, the 
best visual outcomes were observed in patients whose 
mean time from first ocular symptom to consultation was 
15 days (SD +19 days).
Syphilis is a sexually transmitted disease caused by the bacterium Treponema pallidum, which can infect al-
most any part of the body (1). Depending on the stage of 
the disease, acquired syphilis is classified into early (prima-
ry, secondary, and early latent) syphilis and late (or tertiary) 
syphilis (2,3). Although most cases of ocular syphilis occur 
in the context of tertiary syphilis, approximately one third 
of reported cases occur in the context of primary and sec-
ondary syphilis (4,5). Uveitis is observed in 0.6%–2.0% of 
patients with syphilis in any stage and up to 9% in patients 
co-infected with syphilis and HIV (HIV) (6–10). Syphi-
litic uveitis is considered a great mimicker because it can 
manifest as anterior uveitis, posterior uveitis, or panuveitis 
(11–13). Failure to recognize the ocular manifestations of 
syphilis or delayed treatment can lead to irreversible visual 
loss (14,15).
Syphilis has recently reemerged in the Western world 
in the context of the HIV crisis and massive sexual behav-
ior changes among men who have sex with men (MSM). 
In 2015, nearly two thirds (62%) of the syphilis cases 
with information on transmission category were reported 
in MSM (16). 
In this context, we set up a retrospective study to re-
view ocular syphilis cases observed during 2012–2015 
in a tertiary reference center in Paris, France. Our objec-
tives were to analyze trends in ocular syphilis frequen-
cy, demographic characteristics, clinical severity, and 
patient outcome.
Methods
We reviewed the medical records of patients exam-
ined at the uveitis clinic (Centre Hospitalier National 
d’Ophtalmologie des Quinze-Vingts, Paris, France) from 
January 2012 through December 2015. We retrospectively 
identified patients with a new diagnosis of ocular syphilis. 
During the study period, 1,493 new patients were exam-
ined for uveitis. Patients meeting all the following criteria 
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were included: age >18 years, having intraocular inflam-
mation specifically affecting the uvea, and having a syphi-
lis infection confirmed by the Venereal Disease Research 
Laboratory (VDRL) test. We defined a positive serologic 
test result as a positive T. pallidum hemagglutination assay 
(TPHA) and a positive VDRL test result in accordance with 
the classification of syphilis (17,18). We used a standard-
ized strategy to diagnose uveitis (19), including anti-Trepo-
nema antibody detection in all patients in whom uveitis was 
diagnosed, with additional tests guided by the clinical con-
text and paraclinical findings. 
We reviewed files to collect the following data: demo-
graphic information, including MSM status (in case of sex-
ually transmitted disease, sexual orientation was recorded 
in the patient’s confidential file according to national ethics 
guidelines); duration of symptoms before diagnosis; and 
history of extraophthalmologic signs. Ophthalmologic ex-
amination included the measurement of the best-corrected 
visual acuity (BCVA) at initial presentation, at 15 days, and 
at the last follow-up. We converted BCVA to a visual acu-
ity (VA) score on the basis of the logarithm of the mini-
mum angle of resolution (logMAR).
We examined results from the slit lamp examination 
(in the anterior segment of the eye) and the fundus exami-
nation. We used the most informative imaging modality in 
patients with retinal inflammation, fundus fluorescein angi-
ography, to report characteristic features of retinal vascu-
litis, optic nerve head inflammation, and macular edema. 
We used other fundus imaging studies such as indocyanine 
green angiography to assist in cases of choroidal inflam-
mation, fundus autofluorescence imaging to assess retinal 
pigment epithelium integrity, and spectral-domain optical 
coherence tomography to evaluate retinal damage.
Applying the International Uveitis Study Group cri-
teria, we classified uveitis into the following subtypes ac-
cording to the site of inflammation: anterior uveitis, inter-
mediate uveitis, posterior uveitis, or panuveitis (20,21). We 
considered placoid chorioretinitis to be the presence of >1 
placoid, yellowish, outer retinal lesions. Fundus fluorescein 
angiography, indocyanine green angiography, and fundus 
autofluorescence indicate a typical fluorescent pattern in 
cases of placoid chorioretinitis (22,23).
Biological data included the results of treponemal and 
HIV serologic tests and the results of cerebrospinal fluid 
(CSF) analysis. The decision to perform lumbar puncture 
was left to the clinician’s discretion. We defined neuro-
syphilis as positive results in nontreponemal and trepo-
nemal serologic tests, combined with neurologic and CSF 
abnormalities, such as high leukocyte or protein concentra-
tions (>0.5 g/L), and 1 CSF abnormality, such as positive 
VDRL or fluorescent treponemal antibody absorption test 
results (24–26) or a positive PCR test result for T. palli-
dum. Treatment and outcome data included the type, dose, 
duration, and route of antibiotic administration and corti-
costeroid treatment (local or systemic) as well as final VA.
We tested data variable distributions for normality and, 
when appropriate, we performed t-tests or equivalent non-
parametric tests. We used 1-way analysis of variance when 
>3 groups were present and defined statistical significance 
as p<0.05. We analyzed the data by using R 3.2.2 software 
(https://cran.rproject.org/bin/windows/base/old/3.2.2).
Results
We identified 21 cases of ocular syphilis (29 eyes) during 
January 2012–December 2015. Visits to outpatient clinics 
for confirmed ocular syphilis (the number of cases com-
pared to the number of consultations for uveitis) increased 
from 1 in 2012 to 5 in 2013, 6 in 2014, and 9 in 2015 
(2.22–25.21 visits/1,000 individual patients per year for the 
period) (Figure 1).
Demographic Data, Biologic Data, and Clinical Features
Twenty-one patients were affected, all men. The median 
age at presentation was 49 years (range 22–72 years). No 
difference in the mean age of patients was observed at di-
agnosis of ocular syphilis in 2013, 2014, and 2015. Median 
follow-up was 2 months (range 1–22 months).
At the time of uveitis diagnosis, 14 (67%) patients re-
ported extraophthalmologic features, including rash, ulcer, 
mucocutaneous lesions, or neurologic signs. We noted the 
stages of syphilis and the presence of neurosyphilis in the 
21 patients with ocular syphilis (Figure 2). Tertiary syphilis 
was diagnosed in only 1 (5%) patient, secondary syphilis in 
11 (52%) patients, and an undetermined stage of syphilis 
in 9 (43%) patients. Of the 14 patients who had a lumbar 
puncture to assess CSF for evidence of neurosyphilis, 3 
(21%) patients with ocular syphilis had neurosyphilis, and 
in 7 (50%) patients the CSF showed a lymphocytic reac-
tion. We noted the frequency of different clinical presenta-
tions and anatomical types of ocular inflammation (Figure 
3). The mean duration of ophthalmologic symptoms was 
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Figure 1. Number of newly diagnosed ocular syphilis cases 
among patients seen at a uveitis clinic, Paris, France, 2012–2015: 
2012, 1 case; 2013, 5 cases; 2014, 6 cases; 2015, 9 cases.
Ocular Syphilis, France, 2012–2015
1 month before presentation at the uveitis clinic (range 1 
day–4 months).
Isolated posterior uveitis was the most common type 
of uveitis observed within the cohort (69%), followed by 
panuveitis (14%). We summarized the frequency of clini-
cal manifestations in patients with ocular syphilis (Table 
1). Posterior placoid chorioretinitis was the most frequent 
finding in the posterior segment (58% of the total number 
of affected eyes); this condition accounted for 75% of cases 
of syphilis with eye involvement in 2013 and 81% in 2015.
Patients with bilateral impairment had a mean BCVA 
of 0.9 logMAR (range 0–2.30), whereas patients with uni-
lateral disease had a mean BCVA of 1.02 logMAR (p = 
0.54). Worse final VA outcomes (BCVA >0.30 logMAR) 
were found in patients who waited a mean 61 days (SD +53 
days) before seeking medical care. Patients who had the 
best final VA outcome (BCVA <0.30 logMAR) had waited 
a mean 15 days (SD +19 days) before seeking medical care.
Effect of HIV Status
The results of HIV serologic tests were available for all pa-
tients. Six of the 21 patients (29%) were HIV-positive, and 
ocular syphilis led to the eventual diagnosis of HIV infection 
in 2 of these 6 cases. All but 1 of the 6 HIV-positive patients 
were MSM. In patients with ocular syphilis, HIV co-infec-
tion remained stable, ranging 20%–33% during 2012–2015. 
Most of the 21 patients were MSM, including 16 patients in 
the whole cohort and 5 of the 6 HIV-infected patients. These 
percentages did not vary over the study period. 
Subgroup analysis between HIV-negative and HIV-
positive patients found no significant differences in the 
proportion of bilateral disease or initial VA. The clinical 
outcomes for affected eyes was significantly worse for 
HIV-positive patients (final mean BCVA 0.7 logMAR 
[range 0–2.3]) than for HIV-negative patients (0.09 log-
MAR [range 0–0.5]; p = 0.01) (Table 2). Affected eyes 
from HIV-positive patients had no significant difference in 
uveitis type compared with HIV-negative patients.
Treatment
Most of the patients (17/21) were treated with daily intrave-
nous penicillin, 3 patients received intravenous ceftriaxone, 
and 1 received oral doxycycline for 2 weeks followed by 
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Figure 2. Presence of neurosyphilis and stages of syphilis in 21 
patients with ocular syphilis seen at a uveitis clinic, Paris, France, 
2012–2015.
Figure 3. Anatomical sites of ocular inflammation in 21 patients 
with ocular syphilis seen at a uveitis clinic, Paris, France,  
2012–2015.
 
Table 1. Clinical signs among patients with ocular syphilis seen at 
a uveitis clinic, Paris, France, 2012–2015 
Clinical sign No. (%) patients  
Posterior placoid chorioretinitis 17 (58) 
Retinitis 4 (14) 
Optic neuritis 4 (14) 
Anterior uveitis (plus iris gumma) 1 (3.5) 
Neuroretinitis 1 (3. 5) 
Intermediate uveitis 1 (3.5) 
Retinal vasculitis 1 (3.5) 
 
SYNOPSIS
ceftriaxone for 2 weeks. The duration of treatment ranged 
from 2 to 3 weeks, although 2 patients received a total of 4 
weeks of treatment (1 who was treated first with doxycy-
cline and 1 who was diagnosed with tertiary syphilis). The 
penicillin dosage was 24 million IU/day for 13 patients, 
whereas 20 million IU/day was used in 4 patients (includ-
ing 1 who was diagnosed with neurosyphilis). Five of the 7 
patients with neurosyphilis were treated for 2 weeks.
In addition to receiving antibiotic therapy, 11 pa-
tients also received corticosteroid treatment orally (9 pa-
tients),  periocular treatment (4 patients), or both (online 
Technical Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/24/2/17-1167-Techapp1.xlsx). Corticosteroids were 
administered in 4 cases to treat an ocular Jarisch-Herxhei-
mer reaction (JHR) (sudden onset of vitritis, papilledema, 
or both after initiation of systemic antibiotic therapy), and 
in the other 7 cases for persistence of ocular symptoms 
(papillitis, macular edema, or retinal vasculitis) despite ap-
propriate antibiotic therapy. In 1 patient (patient 20), sys-
temic corticosteroids were used to prevent systemic JHR 
(online Technical Appendix Table 2).
Outcomes
Before antimicrobial drug therapy at initial presentation, 
62% of patients had BCVA <0.3 logMAR (20/40 Snel-
len); after antimicrobial drug therapy at final follow-up, 
75% had BCVA >0.3 logMAR (20/40 Snellen) (Figure 4). 
Of the 5 patients with a final BCVA >0.3 logMAR (20/40 
Snellen), only 2 had a treatment delay (<12 weeks); there-
fore, we cannot correlate duration of treatment and visual 
prognosis because of the small number of patients with a 
poor outcome.
Most patients had better final VA than at presenta-
tion, with a mean initial BCVA of 0.9 logMAR (range 
0–2.3) to a mean final BCVA of 0.2 logMAR (range –0.2 
to 2.3). BCVA at presentation did not predict BCVA 
posttreatment (r = 0.5) (Figure 4). All patients had a good 
outcome in terms of quiescence of uveitis and final BCVA 
regardless of whether or not they had been treated with 
systemic or subconjunctival corticosteroids. No statisti-
cally significant difference in final BCVA after treatment 
was found between patients on the basis of whether or 
not they received systemic or subconjunctival corticoste-
roids: 0.40 logMAR (range 0–2.3) versus 0.15 logMAR 
(range –0.2 to 0.5), respectively (p = 0.208). Initial BCVA 
did not significantly differ between patients who had and 
those who had not received systemic or subconjunctival 
corticosteroids (p = 0.627).
In all patients who had lumbar puncture, no statistical 
difference was observed in final visual outcome between 
eyes in which a CSF lymphocytic reaction was diagnosed 
(final BCVA 0.46 [range 0–0.5] logMAR) and eyes with 
no evidence of CSF abnormalities (0.23 [range –0.2 to 2.3] 
logMAR). We also studied differences in syphilis trends 
regarding visual outcomes in 2013, 2014, and 2015. We 
observed no significant differences in visual recovery over 
time (p = 0.5783). In 13 patients for whom >3 months of 
follow-up was available for laboratory testing, quantitative 
VDRL screening was reported to decrease, except in 1 pa-
tient who had recurrence of uveitic syphilis because of an 
interruption in antiretroviral therapy (online Technical Ap-
pendix Table 2).
Discussion
Our study examined the trends in ocular syphilis in pa-
tients attending the uveitis clinic in a tertiary uveitis cen-
ter in France. During the 4-year study period, consistent 
10-fold increase in ocular syphilis was observed. This 
finding is in agreement with an annual epidemiologic re-
port of the European Centre for Disease Prevention and 
Control (ECDC), which observed that in some countries 
in Europe, including France, the United Kingdom, and 
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Table 2. Comparison of HIV-negative and HIV-positive patients with ocular syphilis seen at a uveitis clinic, by epidemiologic 
characteristics, clinical presentations, and outcomes, Paris, France, 2012–2015* 
HIV status 
HIV-negative patients,  
n = 15 patients, 22 eyes 
HIV-positive patients,  
n = 6 patients, 7 eyes p value 
Median age (range), y 48 (32–72) 38.5 (22–61) 0.28 
Median duration from onset of uveitis to presentation (range), d 7 (1–90) 30 (1–120) 0.98 
Uveitis type, no. (% [of 29 eyes])     
 Placoid chorioretinitis 15 (51) 2 (7)  
 Retinitis 2 (7) 2 (7)  
 Optic neuritis 3 (10.5) 1 (3.5)  
 Anterior uveitis (plus iris gumma) 0  1 (3.5)  
 Neuroretinitis 1 (3.5) 0  
 Intermediate uveitis 1 (3.5) 0  
 Retinal vasculitis 1 (3.5) 0  
Bilateral disease, no. (%) 7 (46) 1 (16.5)  
Neurosyphilis, no. (%) 4 (26) 6 (50)  
Mean initial visual acuity (range), logMAR score 0.9 (0–2.3) 1 (0–2) 0.61 
BCVA (range) 2 weeks after starting treatment, logMAR score 0.5 (0–2.3) 1.2 (0.4–2) 0.0030 
BCVA (range) at final follow-up, logMAR score 0.09 (0–0.5) 0.7 (0–2.3) 0.0139 
*BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution.  
 
 
Ocular Syphilis, France, 2012–2015
Germany, a >50% increase in syphilis cases occurred 
during 2010–2014 (16). In France during 2012–2015, the 
number of early syphilis cases increased from nearly 750 
to 1,450 reported cases. This trend was dramatically sharp 
among MSM (27). Indeed, a 15-fold increase was also 
found in the incidence of ocular syphilis in the United 
Kingdom during 1998–2003 (15).
A predominantly male cohort of patients has been re-
ported in all studies, including ours (7,14,22,23,28). In our 
study, 76% of ocular syphilitic cases occurred in MSM. 
The proportion of HIV-positive MSM remained stable dur-
ing the period among ocular syphilis case-patients. A re-
cent report has shown that MSM account for the greatest 
increases in syphilis cases (29). In our study, most case-
patients had syphilis diagnosed during the second stage of 
the disease.
Syphilis is known to display diverse ophthalmolog-
ic manifestations, which our study affirmed. The most 
common finding was posterior uveitis manifesting as 
placoid chorioretinitis (58%), which has been noted in 
previous reports (14,23,29–31). Posterior placoid cho-
rioretinitis is an extremely specific clinical sign for the 
diagnosis of syphilis. Therefore, ≈60% of the patients 
had clinical features consistent with the diagnosis of 
syphilis on retinal imaging even before the diagnosis 
of systemic syphilis was established. Syphilis can be 
highly suspected by the ophthalmologist and requires 
confirmation with blood testing. Moreover, to detect 
other ocular presentations, blood testing for syphilis 
should be included in routine laboratory testing for all 
patients with ocular inflammation. However, clinical 
presentations of other conditions also were identified 
(anterior uveitis, intermediate uveitis, retinitis, and optic 
nerve edema). Notably, only 20% of patients had an inflamed 
anterior segment.
We found disparities in ocular syphilis trends by clinical 
phenotype and evidence of neurosyphilis on CSF analysis 
during the 4-year study period. By clinical feature, the great-
est number of cases of posterior placoid chorioretinitis oc-
curred in 2013 (4 patients) and 2015 (7 patients) and the least 
in 2014 (1 patient). Meanwhile, among the patients who un-
derwent a lumbar puncture, 75% of those with ocular syphi-
lis had a CSF lymphocytic reaction in 2013 (3/4 patients), 
which decreased to 33% in 2014 (2/6 patients) and showed 
an increase again to 50% in 2015 (2/4 patients). These dif-
ferences in ocular syphilitic forms could be related to several 
treponemal strains originating from distinct regions and di-
verse isolation dates (32). Five different strains in 14 patients 
have been identified previously (33).
According to current guidelines, the recommended 
regimen for neurosyphilis and ocular syphilis is benzyl 
penicillin, 18–24 million units/day by intravenous injection 
for 10–14 days (2,3). In our study, this regimen proved to 
be effective. The duration of treatment was similar whether 
or not lumbar puncture confirmed neurosyphilis. Current 
guidelines recommend CSF examination only if patients 
have clinical evidence of neurologic involvement or oph-
thalmic symptoms.
In our study, of 14 case-patients who had undergone 
CSF analysis, 7 (50%) had a lymphocytic reaction and 3 
(21%) had neurosyphilis based on a positive reactive trepo-
nemal or nontreponemal test or PCR test on CSF samples. 
These numbers are consistent with a previous report of 
26% of 31 ocular syphilis case-patients having neurosyphi-
lis diagnosed on CSF examination. In that study, neuro-
syphilis was diagnosed if CSF fluorescent treponemal 
antibody absorption test was reactive or if a lymphocytic 
pleocytosis of >20 cells/μL was detected (34). In contrast, 
the US Centers for Disease Control and Prevention’s esti-
mate of 50%–75% of ocular syphilis patients with evidence 
of neurosyphilis based on a positive CSF VDRL result (35) 
is higher than in our study.
In our study, CSF results did not influence the dura-
tion of treatment or the outcome. Furthermore, the sensi-
tivity of PCR tests on CSF could be questioned because 
sensitivity was low even in intraocular samples. Indeed, 
because of the variable sensitivity of CSF tests (26), no 
CSF test result can definitively exclude a diagnosis of 
neurosyphilis (33). Because experience with PCR tests on 
intraocular fluids is limited (36,37), we suggest not re-
lying on CSF results in such complex cases, preferring 
to examine CSF only when an alternate or concomitant 
infection is suspected (e.g., Herpesviridae and Mycobac-
terium tuberculosis infections), because syphilis is known 
to mimic many other causes of uveitis. Recently, PCR in 
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Figure 4. Visual acuity at initial examination versus final acuity 
(r = 0.5) in 21 patients with ocular syphilis seen at a uveitis clinic, 
Paris, France, 2012–2015.
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CSF has been shown to be highly specific in the diagnosis 
of neurosyphilis (26), offering guidance in case of treat-
ment failure or in supporting the clinical diagnosis of ocu-
lar syphilis or neurosyphilis when several co-infections 
other than syphilis are also detected. Therefore, ocular 
syphilis should be considered in any patient with posi-
tive syphilis serologic tests and ophthalmologic findings 
consistent with ocular syphilis and should be treated with 
a regimen of penicillin appropriate for neurosyphilis re-
gardless of CSF results.
This study has shown that VA on initial examina-
tion did not predict the final visual outcome because 
no correlation existed between BCVA at presentation 
and posttreatment. However, a longer delay in consult-
ing for visual symptoms was associated with worse final 
VA outcomes. We found the best final outcomes (BCVA 
<0.30 logMAR; >6/12 Snellen) in patients whose mean 
time from the first visual symptom to consultation was 
15 days (SD ±19) and, conversely, the worst final BCVA 
(>0.30 logMAR; <6/12 Snellen) in patients whose mean 
time from onset to consultation for visual symptoms was 
2 months (SD +53 days). Similarly, a longer duration be-
tween the first presentation of uveitis and treatment for 
syphilis has been associated previously with a signifi-
cantly higher logMAR VA (e.g., 12 weeks in a study by 
Bollemeijer et al. [31]).
The use of corticosteroids to control the degree of 
inflammation remains undefined in the current treatment 
guidelines. Oral and topical corticosteroids have been 
used in the past in association with antibiotic treatment 
(4,23,38–40). Although topical corticosteroids can be used 
freely to help control anterior segment inflammation (40), 
intravitreal injections of triamcinolone appear to be harm-
ful (39,41). Previous studies highlight the usefulness of 
systemic corticosteroids (intravenous and oral) and peri-
ocular injections to treat macular edema (4), papillitis (23), 
and posterior placoid chorioretinopathy (40). The results of 
our study suggest that the use of periocular or oral steroids 
associated with antibiotic treatment could be useful as ad-
junctive therapy for ocular syphilis in the treatment of ocu-
lar JHR (vitritis), papillitis, and retinal vasculitis. Recently, 
Bollemeijer et al. found no difference in visual outcome 
whether or not patients had received any adjunctive sys-
temic or local steroids; however, they indicate that adjunct 
corticosteroid treatment might have been preferable in the 
most severe cases (31).
If cases of persisting inflammation despite appropri-
ate antibiotic therapy or an ocular JHR, corticosteroids 
seemed to be effective. In our study, improvements in VA 
after the use of periocular injection or systemic cortico-
steroids were observed in all 11 patients, independent of 
the route of corticosteroid administration (intravenous, 
oral, or subconjunctival). No difference in final VA after 
treatment was found between patients who had or had not 
received any adjunctive treatment with systemic or peri-
ocular corticosteroids.
Discrepancies exist in previous reports of HIV co-
infection and visual outcome in syphilitic uveitis. In fact, 
in previous studies, HIV positivity has been associated 
with a worse visual outcome in cases of syphilitic uve-
itis. Other recent studies have not supported this conclu-
sion (1,7,30,42–45). Bollemeijer et al. hypothesized that 
favorable outcomes might be attributable to the immune 
status of HIV-positive patients receiving highly active an-
tiretroviral therapy (31). In our study, 3 of the HIV-posi-
tive patients had CD4+ cell counts <350 cells/µL, which 
might explain the worse visual outcomes associated with 
HIV co-infection. We report worse posttreatment VA in 
HIV-positive patients compared with HIV-negative pa-
tients (Table 2).
The main limitations of this study stem from its in-
trinsic retrospective nature, leading to a heterogeneous 
follow-up schedule for ophthalmic examination. We high-
light the same limitation as noted in previous case series 
(the study was conducted in 1 uveitis center from refer-
rals, so this population might not represent the total spec-
trum of syphilitic uveitis) (31). Nonetheless, we strongly 
believe that the study provides a thorough description of 
the cases of ocular syphilis diagnosed at a reference na-
tional eye center. This report is strengthened by the fact 
that we have epidemiologic information on case-patients, 
including the sex of their sex partners and HIV status, 
as well as ophthalmologic examination and visual out-
come information.
Syphilis can involve visual function, and therefore 
clinicians dealing with patients at risk for syphilis should 
consider that uveitis is one of its potential indications. De-
spite the historic stigma of syphilis and the generally low 
prevalence in the population at large, T. pallidum screen-
ing of patients with uveitis should be conducted (45). The 
nonspecific symptoms of uveitis include severe redness, 
pain, floaters, photophobia, and blurred vision. All patients 
with ocular syphilis should undergo HIV testing and com-
prehensive counseling on the prevention of sexually trans-
mitted diseases. A minimal decline has been observed in 
the number of HIV diagnoses per 100,000 population over 
the past decade. However, the trend by transmission mode 
shows that the number of HIV diagnoses among MSM has 
continued to increase in countries in Europe (46). These 
trends in HIV infection are consistent with the increasing 
incidence of syphilis infection among MSM. At this junc-
ture, the availability of oral HIV preexposure prophylaxis 
and persons’ decisions to rely on it rather than condoms 
might require future evaluation of an increased risk for ocu-
lar impairment attributable to increasing numbers of syphi-
lis infection.
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